SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (1229)10/15/2002 10:37:30 AM
From: tuck  Respond to of 1784
 
Agilent downgraded this morning, and also this from Briefing.com:

>>8:48AM Morning Warnings : IDE guides Q3 to $0.21-$0.22 and Q4 to $0.31-$0.33 vs Multex consensus of $0.31 and $0.41, respectively; BEC sees rev growth of 5% vs previous guidance of 10%; LRW posted Q3 EPS that was $0.02 above consensus, but sees Q4 of $0.04-$0.07 (consensus $0.08).<<

emphasis mine

Doesn't bode well for the trickle companies that are not reagent and mass spec oriented, IMO.

Cheers, Tuck